40 ERIE STREET, CAMBRIDGE, MA
Market cap: $989.2M (12/25/2025)
Price: $9.44
Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
Earnings Release
Other Events
Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)
Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
Financial Results, Changes in Board, Management or Compensation
Intellia Reports Positive 3-Year Data on Lonvo-z for HAE
News
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
PRE 14A
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Confidential Treatment Order
Correspondence
Submission Upload